摘要
收集2005年全年974例化疗患者的病例资料,统计贫血的发生率及贫血的发病程度,分别从年龄、分期、病种、化疗周期累积量、化疗方案、有无消化道反应等方面对贫血发生的影响进行统计学分析。结果:974例化疗后贫血发生率为53.59%,其中轻度贫血38.09%,中度贫血12.11%,重度贫血3.39%;淋巴瘤发生率最高64.58%;≥60岁60.40%,<60岁47.84%,两者差异有统计学意义,P=0.000;Ⅰ+Ⅱ期37.56%,Ⅲ+Ⅳ期55.32%,两者差异有统计学意义,P=0.000;肺癌贫血的发生受化疗的影响最明显,P=0.022。化疗方案中以CHOP方案对血红蛋白(Hb)影响最大,化疗后Hb平均下降4.7g/L。化疗引起的消化道反应和化疗周期累积量对贫血的影响不明显,P>0.05。初步研究结果提示,肿瘤患者贫血的发生率很高,尤其是化疗期间,贫血不但严重影响患者生活质量,而且影响化疗疗效。因此,对存在上述具有统计学价值的人群、疾病应引起临床医师的重视,化疗同时进行早期干预贫血的治疗具有重要临床意义。
The objective of this study was to retrospectively analyse the anaemia incidence of cancer patients receiving chemotherapy. In 974 cancer patients receiving chemotherapy, the realationship among haemoglobin decrease and age, tumor type, stage, chemotherapy cycle cumulation, chemotherapy project, nausea and vomiting and so on was analysed. The incidence of anaemia was 53.59 %, mild anaemia was recorded as 38.09 %, moderate anaemia was 12.11%, and severe anaemia was 3. 39%. The incidence of anaemia was the highest in patients with lymphoma （64.58%）. Age≥60 years was recorded as 60. 40% and age〈60 years as 47.84%, P=0. 000; Ⅰ ＋ Ⅱ stage was recorded as 37.56% and Ⅲ ＋Ⅳ as 55.32%, P 0. 000. The anaemia incidence of the patients with lung cancer significantly correlated with chemotherapy in a cycle, P=0. 022; the chemotherapy project CHOP had a great effect on anaemia, but nausea and vomiting and chemotherapy cycle cumulation had no effect on anaemia in a cycle. In conclusion, the anaemia incidence in cancer patients is high, especially while receiving chemotherapy. Anaemia correlates significantly with the quality of life and therapeutic effect. So early intervention in anaemia has clinical significance in cancer patients receiving chemotherapy.
出处
《中华肿瘤防治杂志》
CAS
2007年第23期1825-1826,共2页
Chinese Journal of Cancer Prevention and Treatment
